Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

FDA Approves Trogarzo For Treatment Of HIV-1 Infection

By The U.S. Food and Drug Administration | March 8, 2018

The FDA approved Trogarzo (ibalizumab-uiyk), a human immunodeficiency virus type 1 (HIV-1) antiretroviral drug, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. The approved recommended dosage of Trogarzo is a single intravenous (IV) loading dose of 2,000 mg followed by a maintenance IV dose of 800 mg every two weeks. Trogarzo is administered after dilution in 250 mL of 0.9 percent sodium chloride injection, USP.

Immune reconstitution inflammatory syndrome has been reported with Trogarzo in combination with other antiretrovirals. During the initial phase of combination antiretroviral therapies, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections, which may necessitate further evaluation and treatment.

Mechanism of Action (MOA), General Pharmacokinetics (PK), and Pharmacodynamics (PD)
  • MOA: Ibalizumab-uiyk, a recombinant humanized monoclonal antibody, is a CD4 domain 2-directed post-attachment HIV-1 inhibitor.
  • Dose Proportionality : Following single-dose administrations of ibalizumab-uiyk as 0.5 to 1.5-hour infusions, AUC increased in a greater than dose-proportional manner, clearance decreased from 9.54 to 0.36 mL/h/kg, and elimination half-life increased from 2.7 to 64 hours as the dose increased from 0.3 to 25 mg/kg (0.01 to 0.9 times the approved recommended loading dose based on a 70 kg patient). 
  • Time to Steady-State: Steady-state concentrations were achieved after the first maintenance dose.
  • Distribution: The volume of distribution of ibalizumab-uiyk was 4.8 L.
  • Immunogenicity: All subjects enrolled in clinical trials were tested for presence of anti-ibalizumab antibodies. One sample tested positive with low titer anti-ibalizumab antibodies. No adverse reaction or reduced efficacy was attributed to the positive sample reported in this subject. 
Efficacy and Safety

Efficacy of Trogarzo was demonstrated in a single arm, multicenter clinical trial of heavily treatment-experienced HIV-infected subjects with multidrug resistant HIV-1. Additional information regarding the efficacy trial can be found in the full prescribing information linked below.

The most common adverse reactions (incidence ≥ 5%) were diarrhea, dizziness, nausea, and rash.

(Source: The U.S. Food And Drug Saftey Administration)

Related Articles Read More >

Data
The COVID-19 effect: Research platforms require new capabilities
COVID-19 vaccine
Is there a link between Bell’s palsy and COVID-19 vaccines?
Johnson & Johnson
8 things to keep in mind related to the FDA advisory meeting on J&J vaccine
Johnson & Johnson
Is J&J’s COVID-19 vaccine linked to tinnitus? 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards